ClinicalTrials.gg
RecruitingNCT06494059Updated Apr 23, 2026

A Novel Repetitive Synchronized Associative Stimulation Neuromodulation Approach for Spinal Cord Injury Patients

An interventional study of Intermittent theta burst stimulation (iTBS) and Functional electrical stimulation (FES) in SCI - Spinal Cord Injury, sponsored by University of Miami. Recruiting at 1 site in United States. Open to participants aged 18 Years to 70 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-04-23.

Sponsored by University of Miami · Not applicable, Interventional, and Basic science

How we know · 2 judgments

From the registry’s dates

  • Started Nov 2024; still recruiting 2 years later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
25
Allocation
Non-randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 45 studies in Spinal Cord Injuries by University of Miami — 12 open to participants now, 14 under way, 1 of them phase 3. Spinal Cord Injuries · University of Miami.

Planned enrollment
20th of 37
25 · median 26
Started
2024
with 5 others
No phase
33 of 45
10 open now
Primary completion
2026-12
later than 0 of 13 live
Registered
38th of 45
by date

Among the 45 studies in Spinal Cord Injuries by University of Miami, this one is the 20th largest by planned enrollment of the 37 interventional ones that give a count, is one of 6 that started in 2024, is one of 33 with no phase, reaches primary completion later than 0 of the 13 other live ones, and was the 38th registered.

Spinal Cord Injuries

2,032 studies on the registry are indexed under Spinal Cord Injuries; 542 are open to participants now.

Browse Spinal Cord Injuries studies →

Open to participants now

12 of the 45 studies in Spinal Cord Injuries by University of Miami are open now, in 1 country. Recruiting first, the newest first:

6 more — sign in →

By country, each count listing its studies:

All 12 open studies →

Where they have run

Who these studies take

Of the 374 Spinal Cord Injuries studies recruiting now, 167 (45%) set no upper age limit and 156 (42%) stop at 75 or younger; 40 take children under 18; 52 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 45 studies in Spinal Cord Injuries by University of Miami, or all of them as a file.
02

Study summary

The purpose of this research is to explore the effect of magnetic stimulation to activate the brain, electrical spinal cord stimulation to activate spinal cord, and electrical muscle stimulation used to activate upper limb (arms), lower limb (legs) and trunk (stomach) muscles in people with spinal cord injury (SCI) and able-bodied subjects (without SCI).

03

Conditions studied

  • SCI - Spinal Cord Injury
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Male or Female subjects

  1. At least 18 years old and no older than 70 years old at the time of enrollment.
  2. Able-bodied subjects
  3. Traumatic spinal cord injury
  4. Upper limb target: neurological level at or above Thoracic 1 level, Abbreviated Injury Scale (AIS) B, C or D impairment grade, primary non-ambulatory;

    • Lower limb target: neurological level at or above Thoracic 10 level, with residual lower limb function; AIS B, C or D impairment grade primary could ambulate;
    • Trunk target: neurological at or above Thoracic 5, AIS A, B, C or D impairment grade, primary wheelchair user
  5. Spinal cord injury sustained more than 6 months prior to study.
  6. Movement/excitability/etc:

    • Upper limb target: Has detectable residual connection in upper-limb muscles in at least one side confirmed by voluntary electromyography (EMG) or detectable motor evoked potential (MEP) and a visible contraction when functional electrical stimulation (FES) is applied in the hand or wrist muscle at baseline.
    • Lower limb target: Has detectable residual connection in lower-limb muscles in at least one side confirmed by voluntary EMG or detectable MEP and a visible contraction when FES is applied in lower limb ankle plantar or dorsiflexor muscle at baseline.
    • Trunk target: Has detectable residual connection in trunk muscles in at least one side confirmed by voluntary EMG or detectable MEP and a visible contraction when FES is applied in trunk muscle at baseline.
  7. Able to commit to intervention and assessment sessions over a maximum duration of 2 months.

Exclusion criteria

Exclusion Criteria:

  1. Has traumatic brain injury, stroke, multiple sclerosis, or other disorders that could affect neuromotor function.
  2. Has severe spasticity that could prevent the study protocol as determined by the investigator.
  3. Has major executive dysfunction, dementia, depression, neurocognitive impairments, or other major medical co-morbidities.
  4. Has for transcutaneous stimulation using FES or TSCS such as breakdown of skin in the area that will come into contact with electrodes, thrombosis, or skin disease.
  5. Has a poorly managed autonomic dysreflexia that could be triggered by transcranial magnetic stimulation (TMS), FES, or TSCS.
  6. Has a history of prior intracranial surgery or known medical risks that would limit TMS protocols.
  7. Has a history of epilepsy, convulsion or seizures.
  8. Individuals with metal implants in their head or spine near the sites to be stimulated and other implantable devices (e.g., cochlear implants) in the body that could be affected by TMS or TSCS.
  9. Has implanted neurostimulator (e.g., deep brain stimulation (DBS), epidural/subdural, vagal nerve stimulation or VNS).
  10. Has a cardiac pacemaker or intracardiac lines.
  11. Has peripheral neuropathy, including diabetic polyneuropathy and entrapment neuropathy.
  12. Has urinary tract infection, unhealed fracture, contracture, and pressure sore as determined by Braden Scale value of 14 and below.
  13. Individuals who require therapy or other care that could interfere with participation in the study.
  14. Individuals on drugs or any other intervention known to have a potential impact on neuromotor function.
  15. Individuals with substance disorders, including alcoholism and drug abuse.
  16. Individuals who are pregnant, breastfeeding, or the desire to become pregnant during the study.
  17. In the opinion of the investigators, the study is not safe or appropriate for the participant.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
25 participants (estimated)

Study arms

  • Experimental
    Upper-limb (arms) target group

    Quadriplegic individuals with SCI who are primary non-ambulatory (walking) will be in this group for up to 2 months.

    Other: Intermittent theta burst stimulation (iTBS) · Other: Functional electrical stimulation (FES) · Other: Transcutaneous spinal cord stimulation (TSCS) · Other: Sham Intermittent theta burst stimulation (iTBS)

  • Experimental
    Lower-limb (legs) target group

    Quadriplegic or paraplegic individuals with SCI primary who can walk will be in this group for up to 2 months.

    Other: Intermittent theta burst stimulation (iTBS) · Other: Functional electrical stimulation (FES) · Other: Transcutaneous spinal cord stimulation (TSCS) · Other: Sham Intermittent theta burst stimulation (iTBS)

  • Experimental
    Trunk (torso) target group

    Quadriplegic or paraplegic individuals with SCI who are primary wheelchair users will be in this group for up to 2 months.

    Other: Intermittent theta burst stimulation (iTBS) · Other: Functional electrical stimulation (FES) · Other: Transcutaneous spinal cord stimulation (TSCS) · Other: Sham Intermittent theta burst stimulation (iTBS)

  • Active comparator
    Able-bodied target group

    Individuals with no spinal cord injury will be in this group for up to 2 months.

    Other: Intermittent theta burst stimulation (iTBS) · Other: Functional electrical stimulation (FES) · Other: Transcutaneous spinal cord stimulation (TSCS) · Other: Sham Intermittent theta burst stimulation (iTBS)

Interventions

  • OtherIntermittent theta burst stimulation (iTBS)

    iTBS is a magnetic stimulation applied using a magnetic coil that is placed on top of the participants head to activate the brain. It consists of three very rapid bursts of electrical pulses at a frequency of 50 Hz (per burst) delivered at a rate of 5 per second for 2 seconds (10 bursts). The burst of pulses will be repeated every 10 seconds for a total duration of about 3 minutes. The stimulation will be applied to activate the brain regions that control upper limb, lower limb or trunk muscles. Each subject is expected to participate longitudinally at least 9 times over 2 months. Each visit will take approximately 2-3 hours.

  • OtherFunctional electrical stimulation (FES)

    FES is applied using electrodes that stick to the skin over the muscles or nerves. It will will be applied using an electrical stimulator to produce movements of the hand, leg or the trunk. The stimulation intensity will be determined by gradually increasing strength from 20-100 hertz (hz) until the right amount of movement is obtained. Each subject is expected to participate longitudinally at least 9 times over 2 months. Each visit will take approximately 2-3 hours.

  • OtherTranscutaneous spinal cord stimulation (TSCS)

    TSCS is applied using electrodes that stick to the skin over the spinal cord to activate spinal cord. Mild electrical stimulation will be applied to make sure the nerves on the back are activated (switched on). Different stimulation intensities (strength) will be tested at different frequencies (pulses per second) to determine the best setting for activating the nerves on the back. The stimulus current strength will be adjusted between 0-250 milliamperes (mA) and will remain within the self-reported tolerance limit of each participant. Each subject is expected to participate longitudinally at least 9 times over 2 months. Each visit will take approximately 2-3 hours.

  • OtherSham Intermittent theta burst stimulation (iTBS)

    Subjects will be fitted with a magnetic coil that is placed on top of the head that does not deliver any stimulation to the brain. Each subject is expected to participate longitudinally at least 9 times over 2 months.Each visit will take approximately 2-3 hours.

06

What researchers measure

Primary outcomes

  1. Change in nine-hole peg test

    The Nine-Hole Peg Test assesses hand and finger dexterity. It is administered by asking the subject to take the pegs from a container, one by one, and place them into holes on the board as quickly as possible. Participants must then remove the pegs from the holes, one by one, and replace them back into the container. Scores are based on the time taken to complete the activity, recorded in seconds.

    Time frame: baseline, up to 2 months

  2. Change in foot tapping test (FTT)

    FTT assesses motor neuron function and mobility. Participants are seated with the foot on the floor and are asked to tap their foot on the ground as rapidly as possible for 10 seconds while keeping the heel on the ground. The number of taps are counted during the 10 seconds.

    Time frame: baseline, up to 2 months

  3. Change in Function in Sitting Test for people with SCI (FIST-SCI)

    FIST-SCI is a clinical test that will be used to test seated balance. FIST-SCI consists of 14 functional, everyday activities as test items. The items are scored on a 5 point ordinal scale ranging from 0 to 4, with 0 representing the lowest ability and 4 representing normal ability.

    Time frame: baseline, up to 2 months

  4. Change in Motor Evoked Potential (MEP)

    MEP evaluates corticospinal excitability (strength of the connections between the brain and the muscles). The excitability is measured as a peak-to-peak amplitude in millivolts (mV).

    Time frame: baseline, up to 2 months

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2024 (actual). Primary completion is estimated for Dec 2026, 25 months after the start.

Of 791 non-industry interventional studies with no phase under Spinal Cord Injuries, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 65. This study's planned 25 months is below that.

Counting every sponsor, half of 840 studies reached it within 36 months; a quarter within 17 and three quarters within 64.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 2, 2024
First posted
Jul 10, 2024
StartActual
Nov 4, 2024
Primary completionEst.
Dec 30, 2026
CompletionEst.
Dec 30, 2026
Last update
Apr 23, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 23, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06494059
Responsible party
Matija Milosevic (Assistant Professor, University of Miami) — Principal investigator
First posted
Jul 10, 2024
Start date
Nov 4, 2024
Primary completion
Dec 30, 2026 (estimated)
Completion
Dec 30, 2026 (estimated)
Last update
Apr 23, 2026

Study contacts

Deena Cilien, DPT
Contact
dcilien@med.miami.edu
(305) 243-9301
Matija Milosevic, PhD
Contact
mmilosevic@med.miami.edu
(305) 243-3572
Matija Milosevic, PhD
principal investigator · University of Miami

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion